相关实验视频

Updated: Jul 8, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

一个多中心的,回顾性,真实世界的研究免疫相关的不良事件的患者与先进的非小细胞肺癌治疗Pembrolizumab单疗法治疗的患者

A Lerner1, A J X Lee2, H Yan3

  • 1North Middlesex University Hospital, London, UK.

Clinical oncology (Royal College of Radiologists (Great Britain))
|January 21, 2024
PubMed
概括

在非小细胞肺癌 (NSCLC) 中使用 pembrolizumab 的免疫检查点抑制剂免疫疗法表明,与免疫相关的不良事件 (irAEs) 与更好的生存率有关. 然而,严重的IRE与更糟糕的结果相关,而延迟的IRE表明了改善的临床结果.

关键词:
先进的 先进的 先进的 先进的 先进的免疫媒介的不良事件.肺癌是一种肺癌.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...